Elsevier

PET Clinics

Volume 13, Issue 1, January 2018, Pages 33-42
PET Clinics

Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment

https://doi.org/10.1016/j.cpet.2017.08.004Get rights and content

Section snippets

Key points

  • Non–small cell lung cancer (NSCLC) is a heterogeneous disease comprising different histologic and molecular subtypes with distinct clinical characteristics, outcomes, and prognosis.

  • PET has an established role in the diagnosis, staging, and monitoring of therapeutic response in patients with NSCLC.

  • Early therapeutic response on PET is associated with improved outcomes in patients receiving targeted therapies.

  • Newer PET tracers have been developed in hopes of improving the sensitivity and

The genomic landscape of non–small cell lung cancer

NSCLC accounts for 85% of all lung cancer cases and comprises 3 major histologic subtypes with the most common being adenocarcinoma followed by squamous cell carcinoma and less commonly large cell carcinoma.1 Most cases of lung cancer are related to tobacco smoking; however, approximately 10% to 20% of cases occur in patients who have never smoked, and the declining rates of smoking equals a proportional increase of incidence among never smokers.3, 4 Smoking-related lung cancer has a

Response assessment criteria in lung cancer

Early and robust evaluation of tumor response in lung cancer is needed to avoid unnecessary side effects of ineffective treatment and delay switching to a more efficacious alternative therapy.2, 47 Multiple guidelines have been developed to assess therapeutic response in clinical trials as a potential surrogate for survival, such as the World Health Organization (WHO) criteria (1979), Response Evaluation Criteria in Solid Tumors (RECIST) 2000, and RECIST 1.1 (2009). RECIST criteria, a

PET detection of oligoprogressive disease

The most common utility of PET in the clinical setting thus far is in detecting oligometastatic disease, which occurs early in the metastatic process defined by a small number of new metastases with limited progression of disease. It is also useful in determining the best site to biopsy, especially in cases where tumor recurrence is uncertain. Increasingly, patients with EGFR mutation-positive and ALK rearranged NSCLC with oligoprogressive disease are being treated with a combination of local

Summary

In the last few years, substantial progress has been made in the discovery of genomic alterations of lung cancer, illuminating clinically significant somatic mutations and enabling further refinement in the subclassification of NSCLC. The identification of oncogenic drivers together with molecular targeted therapies and newer immunotherapies have changed the way patients with lung cancer are treated, with considerable progress still to be made therapeutically. Functional imaging with PET can

First page preview

First page preview
Click to open first page preview

References (80)

  • K. Sprouffske et al.

    Cancer in light of experimental evolution

    Curr Biol

    (2012)
  • H. Young et al.

    Measurement of clinical and subclinical tumour response using [18F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

    Eur J Cancer

    (1999)
  • F. Duhaylongsod et al.

    Lung tumour growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography

    Ann Thorac Surg

    (1995)
  • X.C. Nguyen et al.

    FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values

    Eur J Radiol

    (2007)
  • I. Bahce et al.

    Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

    Lung Cancer

    (2017)
  • A. Rittmeyer et al.

    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    Lancet

    (2017)
  • S. Stroobants et al.

    18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)

    Eur J Cancer

    (2003)
  • N. Sunaga et al.

    Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

    Lung Cancer

    (2008)
  • A.J. Weickhardt et al.

    Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

    J Thorac Oncol

    (2012)
  • R.J. Hicks

    Role of 18F-FDG PET in assessment of response in non-small cell lung cancer

    J Nucl Med

    (2009)
  • L. Ding et al.

    Somatic mutations affect key pathways in lung adenocarcinoma

    Nature

    (2008)
  • C. Swanton et al.

    Clinical implications of genomic discoveries in lung cancer

    N Engl J Med

    (2016)
  • Comprehensive molecular profiling of lung adenocarcinoma

    Nature

    (2014)
  • M.G. Kris et al.

    Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

    JAMA

    (2014)
  • I.B. Weinstein et al.

    Oncogene addiction

    Cancer Res

    (2008)
  • M.A. Levy et al.

    Translating genomic information into clinical medicine: lung cancer as a paradigm

    Genome Res

    (2012)
  • F. Barlesi et al.

    Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1 year nationwide programme of the French cooperative thoracic intergroup (IFCT)

    Lancet Oncol

    (2016)
  • Comprehensive genomic characterization of squamous cell lung cancers

    Nature

    (2012)
  • E.B. Haura et al.

    Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

    J Clin Oncol

    (2010)
  • F.M. Johnson et al.

    Phase II study of dasatinib in patients with advanced non-small-cell lung cancer

    J Clin Oncol

    (2010)
  • A. Desai et al.

    FGFR signalling as a target for lung cancer therapy

    J Thorac Oncol

    (2015)
  • M.P. Mac Manus et al.

    Positron emission tomography is superior to computed tomography scanning for response-assesment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer

    J Clin Oncol

    (2003)
  • D. Lardinois et al.

    Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography

    N Engl J Med

    (2003)
  • H. Jadvar et al.

    18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization

    J Nucl Med

    (2009)
  • B. Fischer et al.

    Preoperative staging of lung cancer with combined PET-CT

    N Engl J Med

    (2011)
  • N.I. Lindeman et al.

    Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

    Arch Pathol Lab Med

    (2013)
  • L.V. Sequist et al.

    Rociletinib in EGFR-mutated non-small cell lung cancer

    N Engl J Med

    (2015)
  • T.S. Mok et al.

    Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

    N Engl J Med

    (2009)
  • L.V. Sequist et al.

    Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

    J Clin Oncol

    (2013)
  • L. Cameron et al.

    New treatment options for ALK-rearranged non-small cell lung cancer

    Curr Treat Options Oncol

    (2015)
  • Cited by (1)

    • The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer

      2022, Seminars in Nuclear Medicine
      Citation Excerpt :

      For example, retrospective analysis of 89 primarily stage III NSCLC patients undergoing definitive chemoradiotherapy in two prospective trials, found the MTV, whether of nodal, primary or total disease burden, was not predictive of survival suggesting that efficacy of treatment may be more important than baseline disease burden in patients with disease that is treated with curative intent.51 Response to targeted therapies is also qualitatively different to those observed with chemotherapy or radiotherapy with often rapid and marked reduction in FDG-avidity with the onset of treatment, reflecting abrogation of signaling through pathways that lead to metabolic reprogramming.52 Collectively, these results emphasize the need for studies in homogeneously treated patients in addition to evaluation of differing subtypes of lung cancer.

    Disclosure Statement: No relevant conflicts of interest.

    View full text